eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
58 hedge funds and large institutions have $116M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
44% more capital invested
Capital invested by funds: $80.3M → $116M (+$35.5M)
35% more funds holding
Funds holding: 43 → 58 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$8.36M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$4.8M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$4.24M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.65M |
| 5 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$2.92M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.24M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$240K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$230K |
| 5 |
RA
Ramius Advisors
New York
|
-$168K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WMSA
51
Weiss Multi-Strategy Advisers
New York
| $148K | +$148K | +600 | New |
|
52
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $138K | – | – | – |
|
|
CCM
53
Context Capital Management
Lajolla,
California
| $95K | +$95K | +386 | New |
|
54
UBS Group
Zurich,
Switzerland
| $20K | +$19.7K | +80 | New |
|
|
MI
55
MMCAP International
Grand Cayman,
Cayman Islands
| $6.19K | +$1.23M | +5,018 | +25% |
|
56
Morgan Stanley
New York
| $6K | +$984 | +4 | +20% |
|
|
PA
57
Parallel Advisors
San Francisco,
California
| $2K | +$2.46K | +10 | New |
|
58
Walleye Capital
New York
| $297 | +$295K | +1,200 | New |
|
|
59
Blackstone Inc
New York
| – | -$2.92M | -12,000 | Closed |
|
|
SSA
60
Schonfeld Strategic Advisors
New York
| – | -$1.24M | -5,131 | Closed |
|
|
61
HighTower Advisors
Chicago,
Illinois
| – | -$240K | -1,001 | Closed |
|
|
FTUS
62
Flow Traders U.S.
New York
| – | -$230K | -934 | Closed |
|
|
RA
63
Ramius Advisors
New York
| – | -$168K | -688 | Closed |
|
EFTR Hedge Fund Activity: Q2 2021 in Review
58 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2021, worth a combined $116M — up 44% from $80.3M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EFTR positions and 5 closed out — a net gain of 15 holders — while 15 added to existing stakes and 3 trimmed.
The largest buyer was Aristeia Capital, adding an estimated $8.36M. The largest seller was Blackstone Inc, exiting entirely with an estimated $2.92M sold.
- 58 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2021, up from 43 in Q1 2021.
- Funds reported $116M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2021, up 44% quarter-over-quarter.
- 20 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2021 and 5 closed out, a net change of +15 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2021 was Aristeia Capital, an estimated $8.36M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2021 was Blackstone Inc, an estimated $2.92M sold.
Based on aggregated 13F filings for Q2 2021.